ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its second quarter 2021 financial results after market close on August 9, 2021. A conference call and webcast will follow at 5:00 p.m. ET to discuss the results. Interested participants can join by calling (877) 303-8028 domestically or (760) 536-5167 internationally. The company's lead drug candidate, avacopan (CCX168), is in late-stage clinical development for severe Hidradenitis Suppurativa and C3 glomerulopathy, following a successful Phase III trial in ANCA-associated vasculitis.

Positive

• Avacopan (CCX168) successfully completed a pivotal Phase III trial in ANCA-associated vasculitis.
• The company is advancing late-stage clinical development for severe Hidradenitis Suppurativa and C3 glomerulopathy.

Negative

• None.

MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market close on Monday, August 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 2164528. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and is in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will ChemoCentryx release its Q2 2021 financial results?

ChemoCentryx will release its second quarter 2021 financial results after market close on August 9, 2021.

What is the main drug candidate of ChemoCentryx?

ChemoCentryx's lead drug candidate is avacopan (CCX168), which targets inflammatory and autoimmune diseases.

What key developments are expected during the ChemoCentryx conference call?

The conference call will discuss the Q2 2021 financial results and provide updates on ongoing clinical developments.

How can I participate in the ChemoCentryx conference call?

To participate by phone, call (877) 303-8028 domestically or (760) 536-5167 internationally, using conference ID 2164528.